DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid … Read more

The Pulse – Biopharma Week in Review: Vertex’s $10B Deal, Keytruda Bladder Win

The Pulse - Biopharma this Week (july 6 - 12, 2026)

The Pulse – Weekly biopharma intelligence – Synopulse Synopulse The Pulse Synopulse’s weekly biopharma briefing – deals, approvals, readouts and access, across every therapy area. WEEKLY6 – 12 July 2026Wk 28 · 2026 The Hub Neurology19 Onco+Immuno30 CardioMeta17 Approvals The big events this week Deal Vertex acquires Crinetics for $10 billion The week’s largest transaction … Read more

Weekly Pulse: Policy & Access Rules Rewritten for 2026

Weekly Pulse: Policy & Access Rules Rewritten for 2026

The past week delivered a coordinated sequence of moves that, taken together, quietly reset expectations for how global systems will price, approve, pay for, and ultimately adopt innovation in 2026. What distinguished this week was not the volume of news but its consistency: across borders and agencies, decision-makers leaned into a shared posture, broadened access … Read more

Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24, 2025

Weekly Pulse Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24, 2025

The Reimbursement Landscape Recalibrates As we pause for the Thanksgiving holiday, a sincere thank-you to our readers and partners for your continued engagement. This week’s update reflects a period of meaningful policymaking momentum across major global agencies. Across the U.S., UK, France, Canada and Thailand, agencies delivered firm, directional decisions that shape how hospitals, clinics … Read more

Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025

Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025

The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more